跳至主要内容
临床试验/ACTRN12617000731392
ACTRN12617000731392已完成1 期

The effect of 1,3-butanediol on immunity and tolerability in recreationally active, healthy males at rest.

Auckland University of Technology0 个研究点目标入组 6 人开始时间: 2017年5月19日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
6

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 35 Years(—)
性别
Male

入选标准

  • 未提供

排除标准

  • 未提供

研究者

相似试验

已完成
1 期
The effect of a dietary ketone on immunity, tolerability and performance in well-trained, healthy male cyclists.Exercise-Induced immunosuppressionGastrointestinal distressSystemic symptoms (e.g. dizziness, nausea)Inflammatory and Immune System - Other inflammatory or immune system disordersOral and Gastrointestinal - Normal oral and gastrointestinal development and functionOther - Research that is not of generic health relevance and not applicable to specific health categories listed above
ACTRN12617001347358Auckland University of Technology9
已完成
不适用
Humoral and T-cell responses to a third dose of BNT162b2 and mRNA-1273 COVID-19 Vaccine in Patients with hematological diseases treated with rituximab or obinutuzumab: An observational study.Hematological diseases
JPRN-UMIN000046603Kobe City Medical Center General Hospital, Department of Hematology68
已完成
不适用
Immunological effects of BCG on vaccination with the yellow fever vaccine.Immune modulationmodulation of the immune system10002252
NL-OMON40902niversitair Medisch Centrum Sint Radboud30
尚未招募
3 期
Immunogenicity and safety after vaccinated with BBIBP-CorV (COVID-19 vaccine) in Thai pregnant womePregnant womenCOVID-19SARS-CoV-2 vaccineVaccinePregnantBBIBP-CorVSinopharm
TCTR20210923013Chulabhorn Hospital400
进行中(未招募)
不适用
Evaluation of the immune response and safety of a booster dose of Pfizer's13-valent pneumococcal conjugate vaccine in children primed with 2 dosesof either GSK's 10-valent pneumococcal conjugate vaccine or Pfizer's 13-valent pneumococcal conjugate vaccine in the Slovak RepublicTo induce appropriate protection against pneumococcal disease. Toassess non-inferiority of OPA response for serotype 19A after boosterdose of PCV13 administered between 11-12 months of age in subjectsprimed with 10Pn-PD-DiT vs those primed with PCV13.
EUCTR2012-005367-27-SKBIOVOMED